Skip to content

Cannabidiol (CBD)

Drug Information

Cannabidiol (CBD) is a phytocannabinoid derived from Cannabis species, which is devoid of psychoactive activity, with analgesic, anti-inflammatory activities. Unlike the main psychoactive cannabinoid in marijuana, tetrahydrocannabinol (THC), CBD does not produce euphoria or intoxication. CBD oil is primarily sold as artisanal product in the form of a tincture, concentrate, capsule, topical, spray, or vape oil.

There is currently one FDA-approved drug comprised of CBD. Epidiolex® is a pure, plant-based, pharmaceutical grade cannabidiol (CBD) extract that has proven effective in treating seizures among individuals two years and older with Dravet and Lennox-Gastaut Syndromes. It is consistent and free from contaminants.

Many alleged CBD products contain other cannabinoids, no cannabinoids, or no CBD.  According to research published in JAMA, only 31% of CBD products purchased online contain the amount of CBD advertised on the label. There is no testing requirement to determine the levels of THC or other contaminants, such as mold or fungi. There is also no regulation on the extraction process, which may incorporate toxins such as butane.

In addition, manufacturers of CBD oil claim that their products contain innumerable health benefits such as preventing diabetes, eliminating pain, treating fibromyalgia, post-traumatic stress disorder, and insomnia among others. However, these claims are unsubstantiated as artisanal CBD products have not undergone the rigorous FDA-approval process that ensures that prescription drugs are reliable, pure, and that the benefits of the medication outweigh the risks for the intended population. Because of these unsupported claims, the FDA has sent several warning letters to firms that market unapproved new drugs.

Producers of CBD oil claim it cures just about everything...

so did the company that created asthma cigarettes before the FDA stepped in and developed a rigorous process for approving medicine.


Per the definition of marijuana in section 37-2701 of Idaho Code, CBD is illegal in Idaho. In 2015, CBD was brought to the center of Idaho’s legislative session. The bill, S1146a, promised legal relief for parents of children with uncontrolled epilepsy to obtain CBD oil with up to 0.3% THC from across state lines. In addition to ODP, Idaho State Police, Department of Health and Welfare (DHW), the Idaho Prosecuting Attorney’s Association, the Fraternal Order of Police, the Idaho Police Chief’s Association, the Idaho Sheriff’s Association, and the Idaho Criminal Justice Commission opposed S1146a. Concerns about the bill included:

  • Lab testing
  • Law enforcement
  • Product purity
  • Product dosing and interactions

Despite these concerns, the Idaho legislature passed S1146a. Governor C.L. "Butch" Otter vetoed the measure and, instead, offered a solution by issuing an Executive Order for an Expanded Access Program (EAP). The EAP would provide children with intractable epilepsy access to pharmaceutical grade CBD, Epidiolex, as part of an FDA-approved study. Epidiolex was approved by the FDA in June 2018 and scheduled by the DEA in September 2018. It will soon be  available for prescription and covered by insurance.

The Idaho Office of Drug Policy leads Idaho’s substance abuse policy and prevention efforts by developing and implementing strategic action plans and collaborative partnerships to reduce drug use and related crime,
thereby improving the health and safety of all Idahoans.

ver: 2.1.0 | last updated: